Trial Profile
A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Relugolix (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 16 May 2022 Results of pooled analysis of two studies (HERO study & C27002) assessing safety were presented at the 117th Annual Meeting of the American Urological Association.
- 10 May 2016 Results of interim analysis (n=95) presented at the 111th Annual Meeting of the American Urological Association
- 06 May 2016 Status changed from active, no longer recruiting to completed.